Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Post by deninsaskon Apr 24, 2007 12:06pm
507 Views
Post# 12664780

K2 Principal Fund is in the back door.

K2 Principal Fund is in the back door. The K2 Principal Fund L.P. acquires common shares of NeuroMedix Inc. TORONTO, Apr 24, 2007 (Canada NewsWire via COMTEX News Network) -- The K2 Principal Fund L.P. ("K2") announced that it has acquired 1,725,000 common shares of NeuroMedix Inc. ("NeuroMedix"). As a result of the acquisition of such shares, K2 owns 1,725,000 common shares representing approximately 10.83% of the issued and outstanding common shares of NeuroMedix. The common shares were purchased by K2 on the TSX Venture Exchange. K2 acquired the securities for investment purposes only and may, depending on market and other conditions, increase or decrease its beneficial ownership, control or direction over, or exercise its current rights to acquire, common shares or other securities of NeuroMedix through market transactions, private agreements or otherwise. SOURCE: K2 Principal Fund L.P. Dan Gosselin, The K2 Principal Fund L.P., (416) 365-2155 Copyright (C) 2007 CNW Group. All rights reserved.
Bullboard Posts